Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other

XORTX Therapeutics shareholders approve 1:10 rollback

By The Northwire Desk — AI Analysis Mar 24, 2026 · 20:42 XRTX · 0.64 XORTX Therapeutics Inc
XRTX · Price

Executive Summary

  • XORTX Therapeutics Inc. shareholders approved a share consolidation at the Annual General Meeting held on March 24, 2026, authorizing the board to consolidate common shares on a basis of up to one post-consolidation share for every five pre-consolidation shares.
  • The consolidation is intended to maintain compliance with Nasdaq Stock Market’s continual listing requirements, specifically the condition that shares trade above $1.00 for 10 consecutive days by April 13, 2026.
  • The transaction is pending approval from the TSX Venture Exchange, with trading on a post-consolidation basis to commence on a date to be determined in consultation with the exchange.

Key Details

  • Shareholder Approval: Authorized via ordinary resolution at the annual and special meeting of shareholders on March 24, 2026.
  • Consolidation Ratio: One post-consolidation common share for up to five pre-consolidation common shares.
  • Timeline: The board may implement the consolidation when deemed in the best interest of the company, but no later than one year from the meeting date.
  • Pre-Consolidation Share Count: 6,962,218 common shares issued and outstanding.
  • Post-Consolidation Share Count: Approximately 1,392,443 common shares (exact number subject to fractional share handling).
  • Fractional Share Handling:
    • Fractions less than one-half of a full share are cancelled.
    • Fractions greater than or equal to one-half of a full share are rounded up to the nearest whole number.
  • Regulatory Status: Pending approval of the TSX Venture Exchange.
  • Name Change: The company will not undergo a name change in connection with the consolidation.
  • Trading Resumption: Shares will commence trading on a post-consolidation basis on a date to be determined in consultation with the TSX-V, announced via subsequent news release.
  • Shareholder Instructions: Registered shareholders will receive a letter of transmittal by mail with instructions to exchange share certificates; beneficial shareholders holding shares through brokers/intermediaries are not required to take action.

Notable Quotes

  • No direct quotes from management were included in the provided text.
Read the original news release →

More from XORTX Therapeutics Inc

Jun 15, 2026 · 07:00

Micro-Cap Biotech Secures FDA Pathway Clarity and Capital, but Execution Risk Remains High

Regulatory May 19, 2026 · 07:00

XORTX closes deep-discount offering with half the proceeds going to investor relations, signaling potential desperation and further dilution ahead.

Financings May 18, 2026 · 11:20

XORTX closes fire‑sale offering at a 38% discount, shareholders left to weather prolonged cash drought and dilutive pipeline.

Financings May 14, 2026 · 07:00

XORTX’s Deep-Discount Rescue Financing Signals Desperation as Biotech’s Cash Burn Leaves Investors Underwater

Financings Apr 13, 2026 · 17:00

XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset

M&A / Property Mar 18, 2026 · 16:47

XORTX Therapeutics proposes three director nominees

Financings